David. E. Messenger

David. E. Messenger

Auto-generated profile, based on publicly available information

David. E. Messenger

Department of Coloproctology, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2022 in BJS Open
Verified
Journal Article
Open access
PDF file
POPhilippa Orchard
Philippa Orchard
RPRyan Preece
Ryan Preece
MTMichael G Thomas
Michael G Thomas
SDSteven W Dixon
Steven W Dixon
NWNewton A C S Wong
Newton A C S Wong
DMDavid E Messenger
David E Messenger
Aims: Recent data suggest that the incidence of malignant appendiceal tumours is increasing. This study aimed to determine temporal trends in the incidence of malignant appendiceal tumours within England and a possible influence by demographic factors. Methods: All incident cases of appendiceal tumours in patients aged 20 years and above were identified from the National Cancer Registration and Analysis Service database between 1995 and 2016 using ICD-9/10 codes. Cancers were categorized according to histology. Joinpoint regression analysis was used to investigate changes in age-standardized incidence rates by age, sex, histological subtype and index of multiple deprivation quintiles, based on socioeconomic domains (income, employment, education, health, crime, barriers to housing and services and living environment). Average annual per cent changes (AAPCs) were estimated by performing Monte-Carlo permutation analysis. Results: A total of 7333 tumours were diagnosed and 7056 patients were analysed, comprising 3850 (54.6 per cent) neuroendocrine tumours (NETs), 1892 (26.8 per cent) mucinous adenocarcinomas and 1314 (18.6 per cent) adenocarcinoma (not otherwise specified). The overall incidence of appendiceal tumours increased from 0.3 per 100 000 to 1.6 per 100 000 over the study interval. Incidence rate increases of comparable magnitude were observed across all age groups, but the AAPC was highest among patients aged 20–29 years (15.6 per cent, 95 per cent c.i 12.7–18.6 per cent) and 30–39 years (14.2 per cent, 12.2–16.2 per cent) and lowest among those aged 70–79 years (6.8 per cent, 5.7–8.0 per cent). Similar incidence rate increases were reported across all socioeconomic deprivation quintiles and in both sexes. Analysis by grade of NET showed that grade 1 tumours accounted for 63 per cent between 2010 and 2013, compared with 2 per cent between 2000 and 2003. Conclusions: The incidence rate of malignant appendiceal tumours has increased significantly since 1995 and is mainly attributed to an increase in NETs. The increased diagnosis of low-grade NETs may in part be due to changes in pathological classification systems.

3 November 2020 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
TMTom A. Maccabe
Tom A. Maccabe
IPIram Parwaiz
Iram Parwaiz
RLRobert J. Longman
Robert J. Longman
MTMichael G. Thomas
Michael G. Thomas
DMDavid E. Messenger
David E. Messenger

1 August 2019 in Health Technology Assessment
Verified
Journal Article
Closed access
BRBarnaby C Reeves
Barnaby C Reeves
LRLeila Rooshenas
Leila Rooshenas
RMRhiannon C Macefield
Rhiannon C Macefield
MWMark Woodward
Mark Woodward
NWNicky J Welton
Nicky J Welton
JBJane M Blazeby
Jane M Blazeby
Background: Surgical site infection (SSI) affects up to 20% of people with a primary closed wound after surgery. Wound dressings may reduce SSI. Objective: To assess the feasibility of a multicentre randomised controlled trial (RCT) to evaluate the effectiveness and cost-effectiveness of dressing types or no dressing to reduce SSI in primary surgical wounds. Design: Phase A – semistructured interviews, outcome measure development, practice survey, literature reviews and value-of-information analysis. Phase B – pilot RCT with qualitative research and questionnaire validation. Patients and the public were involved. Setting: Usual NHS care. Participants: Patients undergoing elective/non-elective abdominal surgery, including caesarean section. Interventions: Phase A – none. Phase B – simple dressing, glue-as-a-dressing (tissue adhesive) or ‘no dressing’. Main outcome measures: Phase A – pilot RCT design; SSI, patient experience and wound management questionnaires; dressing practices; and value-of-information of a RCT. Phase B – participants screened, proportions consented/randomised; acceptability of interventions; adherence; retention; validity and reliability of SSI measure; and cost drivers. Data sources: Phase A – interviews with patients and health-care professionals (HCPs), narrative data from published RCTs and data about dressing practices. Phase B – participants and HCPs in five hospitals. Results: Phase A – we interviewed 102 participants. HCPs interpreted ‘dressing’ variably and reported using available products. HCPs suggested practical/clinical reasons for dressing use, acknowledged the weak evidence base and felt that a RCT including a ‘no dressing’ group was acceptable. A survey showed that 68% of 1769 wounds (727 participants) had simple dressings and 27% had glue-as-a-dressing. Dressings were used similarly in elective and non-elective surgery. The SSI questionnaire was developed from a content analysis of existing SSI tools and interviews, yielding 19 domains and 16 items. A main RCT would be valuable to the NHS at a willingness to pay of £20,000 per quality-adjusted life-year. Phase B – from 4 March 2016 to 30 November 2016, we approached 862 patients for the pilot RCT; 81.1% were eligible, 59.4% consented and 394 were randomised (simple, n = 133; glue, n = 129; no dressing, n = 132); non-adherence was 3 out of 133, 8 out of 129 and 20 out of 132, respectively. SSI occurred in 51 out of 281 participants. We interviewed 55 participants. All dressing strategies were acceptable to stakeholders, with no indication that adherence was problematic. Adherence aids and patients’ understanding of their allocated dressing appeared to be key. The SSI questionnaire response rate overall was 67.2%. Items in the SSI questionnaire fitted a single scale, which had good reliability (test–retest and Cronbach’s alpha of > 0.7) and diagnostic accuracy (c-statistic = 0.906). The key cost drivers were hospital appointments, dressings and redressings, use of new medicines and primary care appointments. Limitations: Multiple activities, often in parallel, were challenging to co-ordinate. An amendment took 4 months, restricting recruitment to the pilot RCT. Only 67% of participants completed the SSI questionnaire. We could not implement photography in theatres. Conclusions: A main RCT of dressing strategies is feasible and would be valuable to the NHS. The SSI questionnaire is sufficiently accurate to be used as the primary outcome. A main trial with three groups (as in the pilot) would be valuable to the NHS, using a primary outcome of SSI at discharge and patient-reported SSI symptoms at 4–8 weeks. Trial registration: Phase A – Current Controlled Trials ISRCTN06792113; Phase B – Current Controlled Trials ISRCTN49328913. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 39. See the NIHR Journals Library website for further project information. Funding was also provided by the Medical Research Council ConDuCT-II Hub (reference number MR/K025643/1).

22 August 2025 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MBMelissa Barlow
Melissa Barlow
DMDavid Messenger
David Messenger
RPRyan Preece
Ryan Preece
APAmy Prowse
Amy Prowse
GAGary Abel
Gary Abel
SBSarah Bailey
Sarah Bailey
Background: The incidence of early-onset colorectal cancer (EOCRC) is rising rapidly, with diagnoses typically occurring at a more advanced stage than late-onset CRC. In the absence of screening for younger patients, diagnosis relies on symptomatic presentation. The faecal immunochemical test (FIT) is a diagnostic triage tool for patients presenting with clinical features of CRC in primary care, though its performance in individuals under 50 years is not well established. Methods: A cohort of 38,117 symptomatic patients aged 18–49 years in upper South West England underwent FIT in primary care between 01/01/2021 and 10/07/2023. A FIT result of ≥10 µg Hb/g faeces was considered positive. In the same region, 528 EOCRC diagnoses were recorded between 01/01/2021 and 10/10/2024. Results: Of the 528 EOCRC patients, 105 (20%) underwent FIT in the year before diagnosis. The sensitivity of FIT was 92.4% (95% CI 85.5–96.7%), specificity was 88.5% (88.2–88.8%), positive predictive value (PPV) was 2.2% (1.8–2.6%), and negative predictive value was 100% (100–100%). PPVs decreased in younger age groups (18–29, 30–39, 40–49 years). Conclusions: FIT performs excellently for patients aged 40–49; however, it may not be used optimally in patients <40 years. A more targeted strategy is needed to guide investigation in younger patients.


14 September 2020 in Colorectal Disease
Verified
Journal Article
Open access
PDF file
ACA. C. Chambers
A. C. Chambers
SDS. W. Dixon
S. W. Dixon
PWP. White
P. White
MTM. G. Thomas
M. G. Thomas
AWA. C. Williams
A. C. Williams
DMD. E. Messenger
D. E. Messenger
Aim: Advanced stage presentation of colorectal cancer is associated with poorer survival outcomes, particularly among young adults. This study aimed to determine whether demographic risk factors for advanced stage presentation differed between young and older adults.Method: Individual‐level data on all incident colorectal cancers in people aged 20 years and above were extracted from the National Cancer Registration and Analysis Service database for the years 2012 to 2015. Patients were divided into two cohorts: young‐onset colorectal cancer (YOCC) if aged 20–49 years and older‐onset colorectal cancer (OOCC) if aged 50 years and above. Logistic regression was used to identify risk factors for advanced stage presentation, defined as TNM Stage III or IV, in each cohort.Results: There were 7075 (5.2%) patients in the YOCC cohort and 128 345 (94.8%) patients in the OOCC cohort. Tumours in the YOCC cohort were more likely to be at an advanced stage (67.2% vs 55.3%, P < 0.001) and located distally (63.7% vs 55.4%, P < 0.001). No demographic factor was consistently associated with advanced stage presentation in the YOCC cohort. Among the OOCC cohort, increased social deprivation [OR (Index of Multiple Deprivation quintile 5 vs 1) = 1.11 (95% CI 1.07–1.16), P < 0.001], Black/Black British ethnicity [OR (baseline White) = 1.25 (95% CI 1.11–1.40), P < 0.001] and residence in the East Midlands [OR (baseline London) = 1.11 (95% CI 1.04–1.17), P = 0.001] were associated with advanced stage presentation.Conclusion: Demographic factors associated with advanced disease were influenced by age. The effects of social deprivation and ethnicity were only observed in older adults and mirror trends in screening uptake. Targeted interventions for high‐risk groups are warranted.